The low expression of FDX1 in most tumors and the up-regulation of FDX1 in liver cancer (Zhang et al. 2022), colon cancer (Wang et al. 2022), kidney cancer (Huang et al. 2022), and other bioinformatics analysis can mediate the good prognosis of tumor patients. Here, FDX1 is linked to kidney cancer.